Xin Lang Cai Jing·2025-09-12 04:25Group 1 - The core viewpoint of the news is that Zhaoyan New Drug has seen a significant increase in its stock price, rising by 5.32% to reach 36.25 yuan per share, with a trading volume of 1.357 billion yuan and a turnover rate of 6.15%, resulting in a total market capitalization of 27.169 billion yuan [1] - Zhaoyan New Drug Research Center Co., Ltd. is primarily engaged in non-clinical safety evaluation services for drugs and the sale of preclinical research services and laboratory animals, established on February 25, 1998, and listed on August 25, 2017 [1] Group 2 - According to data from the top ten heavy stocks of funds, Guojin Fund has a significant holding in Zhaoyan New Drug, with the Guojin Xinyi Medical Consumption A fund holding 256,000 shares, accounting for 4.07% of the fund's net value, ranking as the eighth largest heavy stock [2] - The Guojin Xinyi Medical Consumption A fund, established on June 30, 2020, has a latest scale of 32.205 million yuan, with a year-to-date return of 20.05% and a one-year return of 27.2% [2] - The fund manager, Zhang Wang, has been in position for 5 years and 178 days, with the fund's total asset scale at 360 million yuan, achieving the best return of 47.64% and the worst return of -12.63% during his tenure [2]